CorMedix Inc. (CRMD)
NASDAQ: CRMD · Real-Time Price · USD
10.13
-0.69 (-6.38%)
At close: Feb 21, 2025, 4:00 PM
10.20
+0.07 (0.69%)
After-hours: Feb 21, 2025, 7:08 PM EST
CorMedix Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for CorMedix stock have an average target of 15.67, with a low estimate of 12 and a high estimate of 19. The average target predicts an increase of 54.69% from the current stock price of 10.13.
Analyst Consensus: Strong Buy
* Price targets were last updated on Jan 22, 2025.
Analyst Ratings
The average analyst rating for CorMedix stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 4 | 4 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $15 | Strong Buy | Maintains | $15 | +48.08% | Jan 22, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Initiates $15 | Strong Buy | Initiates | $15 | +48.08% | Jan 13, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $11 → $12 | Buy | Maintains | $11 → $12 | +18.46% | Dec 19, 2024 |
| Needham | Needham | Strong Buy Maintains $10 → $18 | Strong Buy | Maintains | $10 → $18 | +77.69% | Oct 31, 2024 |
| Truist Securities | Truist Securities | Strong Buy Maintains $12 → $17 | Strong Buy | Maintains | $12 → $17 | +67.82% | Oct 22, 2024 |
Financial Forecast
Revenue This Year
39.59M
Revenue Next Year
132.58M
from 39.59M
Increased by 234.92%
EPS This Year
-0.41
from -0.91
EPS Next Year
0.59
from -0.41
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 45.6M | 182.8M | 186.3M | |||
| Avg | 39.6M | 132.6M | 162.5M | |||
| Low | 30.9M | 108.9M | 144.5M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | 361.9% | 40.5% | |||
| Avg | - | 234.9% | 22.5% | |||
| Low | - | 175.1% | 9.0% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -0.34 | 0.99 | 1.48 | |||
| Avg | -0.41 | 0.59 | 1.06 | |||
| Low | -0.48 | 0.23 | 0.76 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | 152.6% | |||
| Avg | - | - | 80.4% | |||
| Low | - | - | 30.4% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.